Chelohart
What is it?
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Identity / background source ↗
Research context
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
- Working classification
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —32 angina patients: 22 adjunctive Chelohart; 10 controls.
- Study methods
- —Small comparative institute report; allocation, blinding and outcome interpretation require caution
- Independent replication
- —Independent replication not established in this collection
- Source access
- —Report reproduction linked; source language and review scope shown per record
- Safety evidence
- —Short-term reports do not establish long-term safety or equivalence to current products
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Explore the expanded peptide research collection and unresolved source trails ↗
View this preparation in the Khavinson evidence map ↗
Linked sources
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Explore the research map and unresolved leads ↗
Chelohart: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
The report describes 30-day treatment and exercise-test outcomes.
- Population / setting
- 32 angina patients: 22 adjunctive Chelohart; 10 controls.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- A larger numerical improvement is not necessarily a significant between-group difference. Allocation, blinding and complete adverse-event collection need verification from original study documentation.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.